Systematic Literature Review of Real-World Outcomes of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis
In real-world reports, benralizumab was associated with significant oral corticosteroid-sparing effects and clinical remission in a significant proportion of patients with eosinophilic granulomatosis with polyangiitis.
Authors
- Andrew Menzies-Gow
- Augusto Vaglio (ORCID: https://orcid.org/0000-0002-3814-9172)
- Anat Shavit
- Michael Stokes (ORCID: https://orcid.org/0000-0002-1822-6214)
- David J. Jackson (ORCID: https://orcid.org/0000-0002-2299-868X)
- Stephanie Chen (ORCID: https://orcid.org/0000-0002-9004-3682)
- Ning Ding (ORCID: https://orcid.org/0000-0002-8409-3413)
- Michael E. Wechsler
Institutions
- AstraZeneca (United Kingdom) (GB)
- Ithaka Harbors (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- National Jewish Health (US)
- Meyer Children's Hospital (IT)
- AstraZeneca (Italy) (IT)
- AstraZeneca (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- The Journal of Allergy and Clinical Immunology In Practice
- Published
- 2025-09-05
- DOI
- https://doi.org/10.1016/j.jaip.2025.08.028
- Citations
- 1
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 1.67